- Quantum Leap Healthcare Collaborative and Ambrx Biopharma Inc (NYSE:AMAM) have announced the selection of Ambrx's antibody-drug conjugate (ADC) ARX788 for a new investigational treatment arm in the I-SPY 2.2 TRIAL.
- Sponsored by Quantum Leap, I-SPY 2.2 is an adaptive Phase 2 trial that evaluates emerging targeted agents, allowing those agents to either be combined with less toxic chemotherapeutic regimens or replace cytotoxic chemotherapy entirely.
- ARX788 will be evaluated as a monotherapy, combined with the PD-1 targeting checkpoint inhibitor cemiplimab, in HER2-positive early-stage breast cancer in the neoadjuvant setting.
- Ambrx anticipates the ARX788 arms to begin enrolling patients in May 2022.
- Price Action: AMAM shares are up 10.90% at $4.08 during the market session on the last check Tuesday.
